Chabner Colloquium: Answering the Big Questions in Cancer Research & 2016 STO Annual Meeting
- Start Date:
- Friday, 11 November, 2016
- End Date:
- Saturday, 12 November, 2016 12:00pm
- Oncology, Hematology
The 2016 Chabner Colloquium will provide updates on the most promising targets for the development of new cancer treatments. Offered for the sixth year, the 2016 Chabner Colloquium includes presentations on emerging molecular targets for cancer treatments -- with a focus on potentially productive opportunities for collaboration between academia and industry. Physician-scientists from leading U.S. research centers will address work in progress in a broad variety of topics in cancer therapeutics.
Invited speakers hail from renowned institutions and companies such as The Massachusetts General Hospital Cancer Center, the Broad Institute of MIT and Harvard, the Dana-Farber Cancer Institute, Novartis, ADT Pharmaceuticals, Inc., and Gurnet Point Capital.The meeting is named for Dr. Bruce A. Chabner, Allen Distinguished Investigator, Clinical Director, Emeritus at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Founding Editor-in-Chief of The Oncologist. Dr. Chabner designs and leads this annual program. Dr. Chabner states, "It's a unique opportunity to share insights and perspectives between investigators and industry professionals working on novel therapeutic targets that will bring exciting changes in oncology practice in the years ahead."
215 Charles St,
Conference organized by Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: www.sto-online.org.
- 318 Blackwell Street, Suite 270